In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression ...

“We hope this results in approval of sacituzumab govitecan plus pembrolizumab for first-line treatment in our patients with triple-negative breast cancer with tumors that are PD-L1-positive.